Postmarketing surveillance, role of the regulatory authority of drugs.

被引：0

|

作者：

Yañez, R., V

Ortega, G. L.

Coimbra, M. R.

Pauste, I. C.

机构：

来源：

ACTA PHARMACOLOGICA SINICA | 2006年 / 27卷

关键词：

D O I：

暂无

中图分类号：

O6 [化学];

学科分类号：

0703 ;

摘要：

引用

收藏

页码：202 / 202

页数：1

相关论文

共 50 条

[1] POSTMARKETING SURVEILLANCE OF NEW DRUGS
BUCKLEY, EG
[J]. JOURNAL OF THE ROYAL COLLEGE OF GENERAL PRACTITIONERS, 1987, 37 (301): : 337 - 338
[2] POSTMARKETING SURVEILLANCE OF DRUGS - REPLY
ROESER, HP
ROHAN, AP
[J]. MEDICAL JOURNAL OF AUSTRALIA, 1991, 154 (08) : 567 - 567
[3] Postmarketing Surveillance for Oncology Drugs
Viale, Pamela Hallquist
Moore, Susan
[J]. CLINICAL JOURNAL OF ONCOLOGY NURSING, 2008, 12 (06) : 877 - 886
[4] FDA will increase postmarketing surveillance of drugs
Tanne, JH
[J]. BRITISH MEDICAL JOURNAL, 2004, 329 (7476): : 1203 - 1203
[5] POSTMARKETING SURVEILLANCE OF ADVERSE REACTIONS TO DRUGS
SNELL, ES
[J]. BRITISH MEDICAL JOURNAL, 1984, 288 (6424): : 1156 - 1156
[6] POSTMARKETING SURVEILLANCE OF ADVERSE REACTIONS TO DRUGS
RAWLINS, MD
[J]. BRITISH MEDICAL JOURNAL, 1984, 288 (6421): : 879 - 880
[7] POSTMARKETING SURVEILLANCE AND THE ROLE OF THE PHARMACIST
DEKONING, GHP
[J]. PROGRESS IN CLINICAL PHARMACY: RATIONAL USE OF DRUGS, 1989, : 163 - 168
[8] POSTMARKETING SURVEILLANCE OF PSYCHOTHERAPEUTIC DRUGS - CONCLUDING COMMENTS
HOLLISTER, LE
[J]. PSYCHOPHARMACOLOGY BULLETIN, 1987, 23 (03) : 405 - 406
[9] Strategies for Postmarketing Surveillance of Drugs for Rare Diseases
Kesselheim, A. S.
Gagne, J. J.
[J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (03) : 265 - 268
[10] POSTMARKETING SURVEILLANCE OF DRUGS - AN OVERVIEW OF THE NEED AND THE METHODOLOGY
ROSENBAUM, SE
[J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1990, 16 (16) : 2431 - 2448

← 1 2 3 4 5 →